search
epigenetics
Trends
- 1
Researchers report that epigenetic editing can silence and eliminate the hepatitis B virus, offering a potential path toward a functional cure for the chronic infection. The approach targets the viral genetic material without cutting DNA, and the findings, reported by Nature, are being discussed as a promising step for the hundreds of millions living with hepatitis B worldwide.
- 2AI reads chemical instructions guiding embryo cell development▼AI can read the chemical instructions that tell embryo cells what to become
Researchers have developed artificial intelligence capable of interpreting the chemical signals, or epigenetic instructions, that determine what type of cell an embryo cell will become. The advance could deepen understanding of early development and birth defects, and raises ethical questions about how far AI should go in decoding the origins of human life.
- 3Epigenetic Editing Edges Closer to Clinical Use▼Epigenetic Editing Steps Closer to the Clinic as Bioengineering Tools Mature
Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.
- 4Academic excerpt links trauma to epigenetic changes●RE: https:// mastodon.social/@Karl_Theodor/ 117217822555924589 Ausszug Hausarbeit - hier # Menschenjagd und # epigenetis
A German-language academic paper excerpt is circulating online, arguing that severe trauma — including rape, abuse and neglect — can leave epigenetic marks, and touching on topics such as manhunts, painkillers and endocrine disruptors. Commenters are engaging with the claim that psychological harm may cause measurable biological changes passed through the body.
- 5Aptadir raises €40M to advance demethylating medicines●Aptadir has €40M warchest to advance demethylating medicines
Spanish biotech Aptadir has secured a €40 million funding package to advance its demethylating medicines, a class of therapies targeting epigenetic changes in cancer cells. The company says the new capital will support development of its pipeline of epigenetic drug candidates as it moves toward clinical progress.